solanezumab

Known as: Immunoglobulin G1, anti-(human beta-amyloid peptide) (humanized monoclonal LY2062430 heavy chain, disulfide with humanized monoclonal LY2062430 light chain, dimer) 
A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Solanezumab recognizes and… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2017
2017
n engl j med 376;18 nejm.org May 4, 2017 science of fatigue than their predecessors were 30 years ago. A second reason is that… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
INTRODUCTION EXPEDITION and EXPEDITION2 were identically designed placebo-controlled phase 3 studies assessing effects of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Despite continuing debate about the amyloid β-protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
Is the amyloid cascade hypothesis of Alzheimer’s disease too big to fail? It proposes that brain deposition of β amyloid protein… (More)
Is this relevant?
2015
2015
Introduction Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss… (More)
Is this relevant?
2014
2014
To the Editor: Salloway et al. (Jan. 23 issue)1 report on two trials of bapineuzumab in mild-tomoderate Alzheimer’s disease, and… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVES To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
BACKGROUND Cerebral vasogenic edema (VE) has been reported to occur during antiamyloid immunotherapy. VE may be associated with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?